Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure.

Chronic heart failure (CHF), as a progressive clinical syndrome, is characterized by failure of enough blood supply from the heart to meet the body's metabolic demands, and there is intense interest in identifying novel biomarkers that could make contributions to the diagnosis of CHF. Metabolomics, compared with current diagnostic approaches, could investigate many metabolic perturbations within biological systems. The overarching goal of the work discussed here is to apply a high-throughput approach to identify metabolic signatures and plasma diagnostic biomarkers underlying CHF by 1H-NMR spectroscopy. Plasma samples from 39 patients with CHF and 15 controls were analyzed by NMR spectroscopy. After processing the data, orthogonal partial least square discriminant analysis (OPLS-DA) was performed. The statistical model revealed good explained variance and predictability, and the diagnostic performance assessed by leave-one-out analysis exhibited 92.31% sensitivity and 86.67% specificity. The OPLS-DA score plots of spectra revealed good separation between case and control on the level of metabolites, and multiple biochemical changes indicated hyperlipidemia, alteration of energy metabolism and other potential biological mechanisms underlying CHF. It was concluded that the NMR-based metabolomics approach demonstrated good performance to identify diagnostic plasma markers and provided new insights into metabolic process related to CHF.

[1]  S. Wold,et al.  Orthogonal projections to latent structures (O‐PLS) , 2002 .

[2]  M. Rantalainen,et al.  OPLS discriminant analysis: combining the strengths of PLS‐DA and SIMCA classification , 2006 .

[3]  Daniel S Waterman,et al.  The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. , 2010, Molecular bioSystems.

[4]  W. Kannel,et al.  Changing epidemiological features of cardiac failure. , 1994, British heart journal.

[5]  Y Wang,et al.  Predictors of readmission among elderly survivors of admission with heart failure. , 2000, American heart journal.

[6]  D. Glower,et al.  Metabolomic Profiling Reveals Distinct Patterns of Myocardial Substrate Use in Humans With Coronary Artery Disease or Left Ventricular Dysfunction During Surgical Ischemia/Reperfusion , 2009, Circulation.

[7]  P. Duez,et al.  Metabolic, nutritional, iatrogenic, and artifactual sources of urinary organic acids: a comprehensive table. , 2002, Clinical chemistry.

[8]  R. Amathieu,et al.  Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis. , 2011, Journal of proteome research.

[9]  Perry M. Elliott,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[10]  H. Nakanishi,et al.  Change in the membranous lipid composition accelerates lipid peroxidation in young rat hearts subjected to 2 weeks of hypoxia followed by hyperoxia. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[11]  Peng Xie,et al.  Plasma metabonomics as a novel diagnostic approach for major depressive disorder. , 2012, Journal of proteome research.

[12]  H. Taegtmeyer,et al.  Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. , 1991, The Journal of clinical investigation.

[13]  B. McManus,et al.  Molecular signatures of end-stage heart failure. , 2011, Journal of cardiac failure.

[14]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[15]  M. Spraul,et al.  750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.

[16]  Jin-Seok Park,et al.  A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. , 2010, Journal of hepatology.

[17]  Kyoungmi Kim,et al.  Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.

[18]  Robert H. G. Schwinger,et al.  Epidemiology and economic burden of chronic heart failure , 2004 .

[19]  D. Kell,et al.  A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations , 2001, Nature Biotechnology.

[20]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[21]  Stanley Nattel,et al.  Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. , 2010, Journal of molecular and cellular cardiology.

[22]  David I. Ellis,et al.  Metabolomics: Current analytical platforms and methodologies , 2005 .

[23]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[24]  C. Pepine,et al.  The role of carnitine in myocardial dysfunction. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[26]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[27]  Walter Kolch,et al.  Urinary Proteomic Biomarkers in Coronary Artery Disease*S , 2008, Molecular & Cellular Proteomics.

[28]  R. Goodacre,et al.  The role of metabolites and metabolomics in clinically applicable biomarkers of disease , 2010, Archives of Toxicology.

[29]  David I. Ellis,et al.  Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate , 2007, Metabolomics.

[30]  J. Garcia-conde,et al.  Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups , 2010, Leukemia.